In a strategic move to advance its brain implant development, Synchron, a competitor of Neuralink, announced on Thursday the acquisition of an equity stake in medical component maker Acquandas. The New York-based company aims to enhance its manufacturing operations for the innovative brain implant.
Synchron has progressed further in the development of its brain implant compared to Elon Musk’s Neuralink. Elon Musk recently revealed that Neuralink had successfully implanted its first device into a human patient. However, Synchron has not disclosed the specific size of the stake acquired or the financial details of the agreement with Acquandas.
Last year, Synchron initiated a second small-scale U.S. trial for its brain implant device, targeting patients with severe paralysis caused by conditions such as amyotrophic lateral sclerosis (ALS), stroke, spinal cord injury, or multiple sclerosis. Like Neuralink, Synchron’s goal is to assist individuals with severe paralysis in controlling digital devices.
Having received approval from the U.S. Food and Drug Administration (FDA) for human testing in July 2021, five years after applying, Synchron continues to strive for advancements in neurotechnology to improve the lives of patients facing severe paralysis.
